Tema Oncology ETF CANC
Set alert
42.29 USD -0.04 -0.09%
At close · Oct 30
42.29 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
42.00 Day range 43.07
30.43 52-week range 45.24
- YTD
- +21.80%
- 1 year
- +37.57%
- Open
- 42.25
- Prev close
- 42.33
- Mkt cap
- 134.36M
- Vol
- 24.93K
- Avg vol
- 24.45K
- EPS
- 1.59
- P/E
- 26.60
- Div yield
- 0.00%
More statistics
- Low
- 42.00
- High
- 43.07
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.30
- 200-d avg
- 27.72
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 27.30
- 200-day average
- 27.72
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
News
- EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert
- Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
- Biotech ETF (CANC) Hits New 52-Week High
- Tema ETFs Exceeds $5bn in AUM After Three Years
- Tema ETFs Surpasses $2 Billion in AUM in Under Three Years
- CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks
- Tema Appoints ETF Industry Leader Steve Munroe as President
- Thrivent Financial for Lutherans Decreases Stake in Tema Oncology ETF $CANC
- Tema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
- The AI Pharma Rally Is Real — And Cancer May Soon Be Chronic, Not Deadly
Your note
Sign in to keep a note on CANC — it syncs with the Stock Master app.